Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex

Aging

Volumn 3, Issue 3, 2011, Pages 189-191

  Major, Philippe ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

mTOR; Rapamycin; Subependymal giant cell astrocytoma; Tuberous sclerosis complex

Indexed keywords

DRUG DERIVATIVE; EVEROLIMUS; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

AGING; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; TUBEROUS SCLEROSIS;

AGING; ASTROCYTOMA; BRAIN NEOPLASMS; HUMANS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

EID: 80051606004     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100298     Document Type: Note

References (17)

1. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460(7253): 392-395.
2. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci. 2010; 1184: 87-105.
3. Reiling JH, Sabatini DM. Stress and mTORture signalling. Oncogene. 2006; 25: 6373-6383.
4. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging. 2009; 1(3): 281-288.
5. Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics. 2010; 41: 199-208.
6. Crino PB, Nathanson KL, Henske EP. The Tuberous Sclerosis Complex. N Engl J Med. 2006; 355: 1345-1356.
7. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann NY Acad Sci. 1991; 615: 125-127.
8. Lyczkowski DA, Conant KD, Pulsifer MB, Jarrett DY, Grant PE, Kwiatkowski DJ, Thiele EA: Intrafamilial phenotypic variability in tuberous sclerosis complex. J Child Neurol. 2007; 22(12):1348-1355.
9. Shepherd CW, Gomez MR, Lie JT, Crowson BA. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc. 1991; 66: 792-796.
10. Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tuberous sclerosis complex. Neurology. 2004; 63: 1457-1461.
11. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin cause regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006; 59: 490-498.
12. Birca A, Mercier C, Major P. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatrics.2010; 6: 381-384.
13. Krueger DA, Care MM, Holland KM, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis. N Engl J Med. 2010; 363:1801-1811.
14. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-151.
15. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008; 14: 843-848.
16. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia. 2010; 51: 27-36.
17. Boobes Y, Bernieh B, Saadi H, Raafat Al Hakim M, Abouchacra S. Gonadal dysfunction and infertility in kidney transplant patients receiving sirolimus. Int Urol Nephrol. 2010; 42(2): 493-498.